Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even though the drug hit only one of two primary endpoints in a pivotal study. In ...

Ashwin Kishtagari, MBBS, is Assistant Professor of Medicine in the division of hematology and oncology at Vanderbilt ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Dr. Prithviraj Bose discussed the current treatment landscape for myeloproliferative neoplasms, a group of rare blood cancers; he focused on myelofibrosis. Dr. Prithviraj Bose, a professor in the ...

Long-term Jakafi exposure increases non-melanoma skin cancer and shingles risk in myelofibrosis patients. Short-term Jakafi exposure is linked to higher pneumonia, sepsis, and urinary tract infection ...

Patients saw a clinical benefit with luspatercept, however it was not statistically significant. Topline data were announced from a phase 3 trial evaluating luspatercept-aamt plus Janus kinase 2 ...

Panelists discuss how distinguishing pre-fibrotic myelofibrosis from other myeloproliferative neoplasms like essential thrombocythemia remains challenging due to overlapping clinical and molecular ...

Vonjo is a medicine called a kinase inhibitor that is used to treat certain types of a blood disorder called myelofibrosis. Myelofibrosis is a type of blood cancer that causes scarring (fibrosis) in ...

Primary myelofibrosis (PMF) is a rare bone marrow disorder that affects the production of blood cells. It causes scarring, or fibrosis, in the bone marrow, which reduces the body’s ability to produce ...

A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem cells that include polycythemia vera and essential thrombocythemia, as well as primary ...

LONDON — A Novartis executive on Thursday said “it’s too early to say” whether the company would still submit an experimental myelofibrosis drug for regulatory approval this year, amid questions about ...

The latest research on the treatment of patients with myelofibrosis (MF) presented at the European Hematology Association (EHA) 2024 annual meeting is reported on by Dr Alessandro Maria Vannucchi of ...